Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
March 17, 2023 08:00 ET
|
Vaxart, Inc.
Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) --...
Vaxart Provides Business Update and Full Year 2022 Financial Results
March 15, 2023 16:01 ET
|
Vaxart, Inc.
Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development Will continue preclinical development of novel COVID-19 vaccine constructs to enhance...
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
March 08, 2023 16:05 ET
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
February 14, 2023 08:00 ET
|
Vaxart, Inc.
Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced...
Vaxart Names Phillip Lee as Chief Financial Officer
December 19, 2022 08:00 ET
|
Vaxart, Inc.
Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Vaxart,...
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
December 01, 2022 08:00 ET
|
Vaxart, Inc.
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to...
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
November 22, 2022 08:30 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World...
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
November 08, 2022 16:01 ET
|
Vaxart, Inc.
Growing body of clinical evidence supports transformational potential of Vaxart’s oral vaccine platform Clinical trial programs on track for reporting key data milestones Ended third quarter with...
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
October 20, 2022 08:30 ET
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
October 10, 2022 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief...